SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VICL (Vical Labs)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Pseudo Biologist who wrote (405)10/26/1997 11:26:00 AM
From: dbuki  Read Replies (1) of 1972
 
Some additional thoughts on the GeneMedicine/Vical patent issue. Since GeneMedicine received a simultaneus patent in Europe, it may very well be challenged there. There is, I believe, a 9-month period after issuance to contest validity. I seem to recall that Schering (Berlin), for example, successfully challenged Biogen's beta-interferon patent oversees. In the U.S. there is no infringement until commercialization occurs. Therefore, research can continue uniterrupted by the entities involved.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News